Thromb Haemost 1994; 72(06): 799-803
DOI: 10.1055/s-0038-1648964
Original Article
Schattauer GmbH Stuttgart

A Single Base Pair Deletion in the Promoter Region of the Factor IX Gene Is Associated with Haemophilia B

Adrian J Hall
The Section of Molecular Genetics, Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield, UK
,
Ampaiwan Chuansumrit
1   The Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Ian R Peake
The Section of Molecular Genetics, Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield, UK
,
Peter R Winship
The Section of Molecular Genetics, Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield, UK
› Author Affiliations
Further Information

Publication History

Received 13 April 1994

Accepted after resubmission 31 August 1994

Publication Date:
06 July 2018 (online)

Summary

Patients with the haemophilia B Leyden phenotype show a distinct pattern of factor IX expression characterized by a post-pubertal increase in FIX levels and the remission of clinical symptoms in adult life. This phenotype has previously been linked to single base mutations within transcription factor binding sites in a region of ∼40 bp around the major start point of transcription of the FIX gene. Here we report a novel mutation in this region within the transcription factor C/EBP binding site at +1 to +18. The mutation is a single base pair deletion from a triplet of thymine residues at +6 to +8. We show that the extent to which this mutation disrupts the binding of C/EBP to its binding site is less marked than the disruption caused by the +13 A→G mutation of FIX Norwich (1). This correlates with age-matched phenotypic data we have available for the patient reported here and that of FIX Norwich.

 
  • References

  • 1 Crossley M, Winship PR, Black A, Rizza CR, Brownlee GG. Unusual case of haemophilia B. Lancet 1989; i: 960
  • 2 Gianelli F, Green PM, High KA, Sommer S, Poon M-C, Ludwig M, Schwab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B: Database of point mutations and short additions and deletions -fourth edition, 1993. Nucleic Acids Res 1993; 21: 3075-3087
  • 3 Veltkamp JJ, Meilof J, Remmetts HG, Van der Vlerk D, Loeliger EA. Another genetic variant of haemophilia B: Haemophilia B Leyden. Scand J Haemat 1970; 7: 82-90
  • 4 Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from haemophilia B Leyden: An androgen-responsive element in the factor IX promoter. Science 1992; 257: 377-379
  • 5 Anson DS, Choo KH, Rees DJG, Gianelli F, Gould K, Huddleston JA, Brownlee GG. The gene structure of human anti-haemophilic factor IX. EMBO J 1984; 3: 1053-1060
  • 6 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (anti-haemophilic factor B). Biochemistry 1985; 24: 3736-3750
  • 7 Reijnen MJ, Sladek FM, Bertina RM, Reitsma PH. Disruption of a binding site for hepatocyte nuclear factor 4 results in haemophilia B Leyden. Proc Natl Acad Sci USA 1992; 89: 6300-6303
  • 8 Reijnen MJ, Peerlinck K, Maasdam D, Bertina RM, Reitsma PH. Haemophilia B Leyden: Substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood 1993; 82: 151-158
  • 9 Crossley M, Brownlee GG. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 1990; 345: 444-446
  • 10 Cotton RGH, Rodrigues NR, Campbell RD. Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci USA 1988; 85: 4397-4401
  • 11 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491
  • 12 Winship PR, Dragon AC. Identification of haemophilia B patients with mutations in the two calcium binding domains of factor IX: importance of a β-OH Asp 64→Asn change. Br J Haemat 1991; 77: 102-109
  • 13 Green PM, Bentley DR, Mibashan RS, Nilsson IM, Gianelli F. Molecular pathology of haemophilia B. EMBO J 1989; 8: 1067-1072
  • 14 Bacteriophage T4 polynucleotide kinase. In: Molecular cloning: A laboratory manual (second edition) Sambrook J, Fritsch EF, Maniatis T. eds Cold Spring Harbor Laboratory Press, Cold Spring Harbor; NY: 1989. pp 5.68-5.69
  • 15 Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1985; 7: 2745-2752
  • 16 Friedman AD, Landschulz WH, McKnight SL. CCAAT enhancer binding-protein activates the promoter of the serum-albumin gene in cultured hepatoma cells. Genes Dev 1989; 3: 1314-1322
  • 17 Beddington RSP, Morgenstern J, Land H, Hogan A. An in situ transgenic enzyme marker for the midgestation mouse embryo and the visualization of inner cell mass clones during early organogenesis. Development 1989; 106: 37-46
  • 18 Herbomel P, Bourachot B, Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 1984; 39: 653-662
  • 19 Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982; 2: 1044-1051
  • 20 Mobility shift DNA-binding assay using gel electrophoresis. In: Current protocols in molceular biology Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Struhl K. eds Wiley Intersciences; NY: 1991. pp 12.2.01-12.2.10
  • 21 Isolation of DNA fragments from polyacrylamide gels. In: Molecular cloning: A laboratory manual (second edition) Sambrook J, Fritsch EF, Maniatis T. eds Cold Spring Harbor Laboratory Press, Cold Spring Harbor; NY: 1989. pp 6.46-6.48
  • 22 Andrews NC, Faller DV. A rapid technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19: 2499
  • 23 Freedenberg DL, Black B. Altered developmental control of the factor IX gene: A new T to A mutation at position +6 of the FIX gene resulting in haemophilia B Leyden. Thromb Haemost 1989; 65: 964 (abstr)
  • 24 Royle G, Van de Water NS, Berg E, Ockelford A, Browett PJ. Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region. Br J Haematol 1991; 77: 191-194
  • 25 Reitsma PH, Mandalaki T, Kasper CK, Bertina RM, Briet E. Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (Haemophilia B Leyden phenotype). Blood 1989; 73: 743-746
  • 26 Koeberl DD, Bottema CDK, Buerstedde JM, Sommer SS. Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG. Am J Hum Genet 1989; 45: 448-457
  • 27 Picketts DJ, Lillicrap DP, Mueller CR. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Nature Gen 1993; 3: 175-179
  • 28 Reijnen MJ, Maasdam D, Bertina RM, Reitsma PH. Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene. Blood Coag Fib 1994; 5: 341-348
  • 29 Simpson NE, Biggs R. The inheritance of Christmas factor. Br J Haematol 1962; 8: 191-203